{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:49:55Z","timestamp":1791611395988,"version":"4.3.4"},"reference-count":30,"publisher":"The Fukushima Society of Medical Science","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.5387\/fms.25-00040","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:09:28Z","timestamp":1776982168000},"page":"303-312","source":"Crossref","is-referenced-by-count":0,"title":["The prognostic significance of pharmacological therapy after cardiac resynchronization therapy"],"prefix":"10.5387","volume":"72","author":[{"given":"Takamasa","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahiro","family":"Murota","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Nodera","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kaneshiro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Heidenreich PA, Bozkurt B, Aguilar D, <i>et al.<\/i> 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, <b>145<\/b> : e895-e1032, 2022.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"2","unstructured":"2. McDonagh TA, Metra M, Adamo M, <i>et al.<\/i> 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J, <b>42<\/b> : 3599-3726, 2021."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. McMurray JJV, Packer M, Desai AS, <i>et al.<\/i> Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med, <b>371<\/b> : 993-1004, 2014.","DOI":"10.1056\/NEJMoa1409077"},{"key":"4","unstructured":"4. McMurray JJV, Solomon SD, Inzucchi SE, <i>et al.<\/i> Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med <b>381<\/b> : 1995-2008, 2019."},{"key":"5","unstructured":"5. Packer M, Anker SD, Butler J, <i>et al.<\/i>   Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med, <b>383<\/b> : 1413-1424, 2020."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sapp JL, Sivakumaran S, Redpath CJ, <i>et al.<\/i> Long-Term Outcomes of Resynchronization\u2013Defibrillation for Heart Failure. N Engl J Med, <b>390<\/b> : 212-220, 2024.","DOI":"10.1056\/NEJMoa2304542"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sudesh S, Abraham WT, Cleland JGF, <i>et al.<\/i> Cardiac Resynchronization Therapy in Ischemic versus Nonischemic Cardiomyopathy : Patient-Level Meta-analysis of 7 Randomized Clinical Trials. JACC Heart Fail, <b>12<\/b> : 1915-1924, 2024.","DOI":"10.1016\/j.jchf.2024.08.010"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Crespo-Leiro MG, Anker SD, Maggioni AP, <i>et al.<\/i> European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT) : 1-year follow-up outcomes and differences across regions. Eur J Heart Fail, <b>18<\/b> : 613-625, 2016.","DOI":"10.1002\/ejhf.566"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Savarese G, Carrero JJ, Pitt B, <i>et al.<\/i> Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction : an analysis of 11,215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail, <b>20<\/b> : 1326-1334, 2018.","DOI":"10.1002\/ejhf.1182"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pitt B, Zannad F, Remme WJ, <i>et al.<\/i> The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, <b>341<\/b> : 709-717, 1999.","DOI":"10.1056\/NEJM199909023411001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tomasoni D, Pagnesi M, Colombo G, <i>et al.<\/i> Guideline-directed medical therapy in severe heart failure with reduced ejection fraction : An analysis from the HELP-HF registry. Eur J Heart Fail, <b>26<\/b> : 327-337, 2024.","DOI":"10.1002\/ejhf.3081"},{"key":"12","unstructured":"12. Greene SJ, Butler J, Albert NM, <i>et al.<\/i> Medical Therapy for Heart Failure with Reduced Ejection Fraction : The CHAMP-HF Registry. J Am Coll Cardiol, <b>72<\/b> : 351-366, 2018."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Varma N, Boehmer J, Bhargava K, <i>et al.<\/i>   Evaluation, Management, and Outcomes of Patients Poorly Responding to Cardiac Resynchronization Therapy. J Am Coll Cardiol, <b>74<\/b> : 2588-2603, 2019.","DOI":"10.1016\/j.jacc.2019.09.043"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsuo S, Imai E, Horio M <i>et al.<\/i> Revised Equations for Estimated GFR From Serum Creatinine in Japan. Am J Kidney Dis, <b>53<\/b> : 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Masuyama T, Tsujino T, Origasa H, <i>et al.<\/i>   Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure\u2013The J-MELODIC Study\u2013. Circ J, <b>76<\/b> : 833-842, 2012.","DOI":"10.1253\/circj.CJ-11-1500"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Naqvi SY, Jawaid A, Vermilye K, <i>et al.<\/i> Left Ventricular Reverse Remodeling in Cardiac Resynchronization Therapy and Long-Term Outcomes. JACC Clin Electrophysiol, <b>5<\/b> : 1001-1010, 2019.","DOI":"10.1016\/j.jacep.2019.07.012"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Oka T, Inoue K, Tanaka K, <i>et al.<\/i> Duration of reverse remodeling response to cardiac resynchronization therapy : Rates, predictors, and clinical outcomes. Int J Cardiol, <b>243<\/b> : 340-346, 2017.","DOI":"10.1016\/j.ijcard.2017.05.058"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bristow MR, Gilbert EM, Abraham WT, <i>et al.<\/i>   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation, <b>94<\/b> : 2807-2816, 1996.","DOI":"10.1161\/01.CIR.94.11.2807"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose and outcomes in advanced heart failure. Am J Cardiol, <b>97<\/b> : 1759-1764, 2006.","DOI":"10.1016\/j.amjcard.2005.12.072"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology, <b>96<\/b> : 132-143, 2001.","DOI":"10.1159\/000047397"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. O\u2019Connor CM, Gattis WA, Uretsky BF, <i>et al.<\/i>   Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : insights from the Flolan International Randomized Survival Trial (FIRST).   Am Heart J, <b>138<\/b> : 78-86, 1999.","DOI":"10.1016\/S0002-8703(99)70250-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Komajda M, Sch\u00f6pe J, Wagenpfeil S, <i>et al.<\/i> Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction : the QUALIFY international registry.   Eur J Heart Fail, <b>21<\/b> : 921-929, 2019.","DOI":"10.1002\/ejhf.1459"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ohata T, Niimi N, Shiraishi Y, <i>et al.<\/i> Initiation and up-titration of guideline-based medications in hospitalized acute heart failure patients\u2015 A report from the West Tokyo heart failure registry. Circ J, <b>88<\/b> : 22-30, 2024.","DOI":"10.1253\/circj.CJ-23-0356"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Greene SJ, Bash LD, Tebbs KW, Hancock LN, Barlow SG, Coyle CR. Physician-Reported Reasons for Not Initiating Guideline-Directed Medical Therapy for Heart Failure. JACC Heart Fail, <b>12<\/b> : 2120-2122, 2024.","DOI":"10.1016\/j.jchf.2024.08.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gorodeski EZ, Magnelli-Reyes C, Moennich LA, Grimaldi A, Rickard J. Cardiac resynchronization therapy-heart failure (CRT-HF) clinic : A novel model of care. PLoS One, <b>14<\/b> : e0222610, 2019.","DOI":"10.1371\/journal.pone.0222610"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gerra L, Bonini N, Mei DA, <i>et al.<\/i> Cardiac resynchronization therapy (CRT) nonresponders in the contemporary era : A state-of-the-art review.   Heart Rhythm, <b>22<\/b> : 159-169, 2025.","DOI":"10.1016\/j.hrthm.2024.05.057"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Schuuring MJ, Treskes RW, Castiello T, <i>et al.<\/i>   Digital solutions to optimize guideline-directed medical therapy prescription rates in patients with heart failure : a clinical consensus statement from the ESC Working Group on e-Cardiology, the Heart Failure Association of the European Society of Cardiology, the Association of Cardiovascular Nursing &amp; Allied Professions of the European Society of Cardiology, the ESC Digital Health Committee, the ESC Council of Cardio-Oncology, and the ESC Patient Forum. Eur Heart J Digit Health, <b>5<\/b> : 670-682, 2024.","DOI":"10.1093\/ehjdh\/ztae064"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zannad F, Ferreira JP, Pocock SJ, <i>et al.<\/i> SGLT2 inhibitors in patients with HFrEF : a meta-analysis of EMPEROR-Reduced and DAPA-HF trials.   Lancet, <b>396<\/b> : 819-829, 2020.","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Armstrong PW, Pieske B, Anstrom KJ, <i>et al.<\/i>   Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med, <b>382<\/b> : 1883-1893, 2020.","DOI":"10.1056\/NEJMoa1915928"},{"key":"30","unstructured":"30. Kitai T, Kosaka S, Kato T, <i>et al.<\/i> JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. J Card Fail, <b>31<\/b> : 1164-1322, 2025."}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/72\/4\/72_25-00040\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:07:35Z","timestamp":1791608855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/72\/4\/72_25-00040\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.25-00040","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25-00040"}}